INT140206

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 1.85
Pain Relevance 2.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (GRM5) cytoplasm (GRM5) signal transducer activity (GRM5)
Anatomy Link Frequency
odontoblasts 1
central nervous system 1
GRM5 (Homo sapiens)
Pain Link Frequency Relevance Heat
opioid receptor 11 100.00 Very High Very High Very High
Central nervous system 3 100.00 Very High Very High Very High
Glutamate receptor 20 99.48 Very High Very High Very High
Pain 5 98.36 Very High Very High Very High
depression 4 97.76 Very High Very High Very High
unmyelinated 1 97.12 Very High Very High Very High
addiction 2 96.52 Very High Very High Very High
antagonist 33 96.12 Very High Very High Very High
Neuropathic pain 2 94.84 High High
agonist 33 90.00 High High
Disease Link Frequency Relevance Heat
Disease 6 98.72 Very High Very High Very High
Pain 3 98.36 Very High Very High Very High
Anxiety Disorder 21 98.12 Very High Very High Very High
Depression 4 97.76 Very High Very High Very High
Schizophrenia 3 97.28 Very High Very High Very High
Neuropathic Pain 3 94.84 High High
Neurodegenerative Disease 1 92.56 High High
Inflammatory Pain 3 89.36 High High
Hyperalgesia 2 87.60 High High
Stress 5 84.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In vitro and in vivo evaluation of [11C]MPEPy as a potential PET ligand for mGlu5 receptors.
mGlu5 Binding (ligand) of
1) Confidence 0.36 Published 2006 Journal Nucl. Med. Biol. Section Title Doc Link 17127176 Disease Relevance 0.37 Pain Relevance 0.55
INTRODUCTION: The metabotropic glutamate receptor subtype 5 (mGluR5) is distributed throughout the central nervous system (CNS), and has been suggested to be a potential target for several CNS disorders suchas Parkinson's disease, pain, anxiety, depression, schizophrenia, and addiction.
mGluR5 Binding (target) of in central nervous system associated with addiction, pain, depression, glutamate receptor, anxiety disorder, central nervous system, disease and schizophrenia
2) Confidence 0.36 Published 2008 Journal Nucl Med Commun Section Abstract Doc Link 18769310 Disease Relevance 0.49 Pain Relevance 0.44
Immunoreactivity for mGluR5 and TRPV1 was also observed in odontoblasts.
mGluR5 Binding (Immunoreactivity) of in odontoblasts
3) Confidence 0.36 Published 2009 Journal J Endod Section Abstract Doc Link 19410084 Disease Relevance 0.50 Pain Relevance 0.51
In addition, co-immunoprecipitation experiments revealed evidence for an interaction between MOR and mGluR5 which is facilitated by MPEP treatment.
mGluR5 Binding (interaction) of associated with opioid receptor
4) Confidence 0.36 Published 2009 Journal Neuropharmacology Section Abstract Doc Link 19162047 Disease Relevance 0 Pain Relevance 0.73
MPEP inhibited [3H]-fenobam binding to human mGlu5 receptors with a Ki value of 6.7 nM, indicating a common binding site shared by both allosteric antagonists.
mGlu5 Binding (binding) of associated with antagonist
5) Confidence 0.22 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2656819 Disease Relevance 0.49 Pain Relevance 0.30
Our prediction of MPEP binding to both active and inactive GRM5 models predicted all of the above residues to be within 5 Å of the ligand, except A809, T780 and Y791 (colored in red in Table 2).
GRM5 Binding (binding) of
6) Confidence 0.15 Published 2008 Journal BMC Bioinformatics Section Body Doc Link PMC2259417 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox